Page 154 - Haematologica May 2022

A. Dodero et al.
11.Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335-1342.
12. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777-783.
13.Barrans SL, Evans PA, O'Connor SJ, et al. The t(14;18) is associated with germinal cen- ter-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res. 2003;9(6):2133-2139.
14. Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irre- spective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013;98(2):255-263.ì
15. Ennishi D, Mottok A, Ben-Neriah S, et al. Genetic profiling of Myc and BCL2 in dif- fuse large B-cell lymphomas determines cell of origin specific clinical impact. Blood. 2017;129(20):2760-2770.
16. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression con- tributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lym- phoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 121(20):4021-4031.
17. Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression pre- dicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014;165(3):382-391.
18. Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182-2188.
19. Dodero A, Guidetti A, Tucci A, et al. Dose- adjusted EPOCH plus rituximab improves
the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia. 2019; 33(4):1047-1051.
20. Hainaut P, Pfeifer GP. Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a026179.
21. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 muta- tion analysis in chronic lymphocytic leukemia. Leukemia. 2012;26(7):1458-1461.
22. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685-2693.
23. McMillan AK, Phillips EH, Kirkwood AA, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemo- therapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31(9):1251-1259.
24. Molina TJ, Canioni D, Copie-Bergman C, et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lym- phoma benefit from intensified chemother- apy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014;32(35):3996-4003.
25. Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.
26. Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R- CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-609.
27.Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B- cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2017;
129(3):280-288.
28. Schuster SJ, Svoboda J, Chong EA, et al.
Chimeric antigen receptor T cells in refrac- tory B-cell lymphomas. N Engl J Med. 2017;377(26):2545-2554.
29. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabta- gene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multi- centre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42.
30.Torka P, Kothari SK, Sundaram S, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Adv. 2020;4(2):253-262.
31.Savage KJ, Slack GW, Mottok A, et al. Impact of dual expressionof MYC and BCL2 by immunohistochemistryon the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182-2188.
32. Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clin- ical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919-926.
33. Leppä S, Jørgensen J, Tierens A, et al. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS pro- phylaxis. Blood Adv. 2020;4(9):1906-1915.
34. Meriranta L, Pasanen A, Alkodsi A, Haukka J, Karjalainen-Lindsberg ML, Leppä S. Molecular background delineates outcome of double protein expressor diffuse large B- cell lymphoma. Blood Adv. 2020; 4(15):3742-3753.
35. Song JY, Perry AM, Herrera AF, et al. Double-hit signature with TP53 abnormal- ities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP. Clin Cancer Res. 2021;27(6):1671-1680.
36. Chiappella A, Diop F, Agostinelli C, et al. TP53 mutation had a negative prognostic impact in untreated young patients with diffuse large B-cell lymphoma at high-risk: a sub-analysis of FIL-DLCL04 study. Hemasphere. 2018;2(S1):711-712.
1162
haematologica | 2022; 107(5)